Literature DB >> 25042852

Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.

Jianguo Wen1, Wenjing Tao, Isere Kuiatse, Pei Lin, Yongdong Feng, Richard J Jones, Robert Z Orlowski, Youli Zu.   

Abstract

Cancer stem cells are key drivers of tumor progression and disease recurrence in multiple myeloma (MM). However, little is known about the regulation of MM stem cells. Here, we show that a population of MM cells, known as the side population (SP), exhibits stem-like properties. Cells that constitute the SP in primary MM isolates are negative or seldom expressed for CD138 and CD20 markers. In addition, the SP population contains stem cells that belong to the same lineage as the mature neoplastic plasma cells. Importantly, our data indicate that the SP and nonside population (NSP) percentages in heterogeneous MM cells are balanced, and that this balance can be achieved through a prolonged in vitro culture. Furthermore, we show that SP cells, with confirmed molecular characteristics of MM stem cells, can be regenerated from purified NSP cell populations. We also show that the percentage of SP cells can be enhanced by the hypoxic stress, which is frequently observed within MM tumors. Finally, hypoxic stress enhanced the expression of transforming growth factor β1 (TGF-β1) and blocking the TGF-β1 signaling pathway inhibited the NSP dedifferentiation. Taken together, these findings indicate that the balance between MM SP and NSP is regulated by environmental factors and TGF-β1 pathway is involved in hypoxia-induced increase of SP population. Understanding the mechanisms that facilitate SP maintenance will accelerate the design of novel therapeutics aimed at controlling these cells in MM.
© 2014 UICC.

Entities:  

Keywords:  cancer stem cells; environmental factors; multiple myeloma; side population

Mesh:

Substances:

Year:  2014        PMID: 25042852      PMCID: PMC4268424          DOI: 10.1002/ijc.29078

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  48 in total

1.  Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.

Authors:  Pavel P Kotouček; Alberto Orfao
Journal:  Br J Haematol       Date:  2014-04-02       Impact factor: 6.998

2.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

3.  Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936.

Authors:  J H J M van Krieken; A W Langerak; E A Macintyre; M Kneba; E Hodges; R Garcia Sanz; G J Morgan; A Parreira; T J Molina; J Cabeçadas; P Gaulard; B Jasani; J F Garcia; M Ott; M L Hannsmann; F Berger; M Hummel; F Davi; M Brüggemann; F L Lavender; E Schuuring; P A S Evans; H White; G Salles; P J T A Groenen; P Gameiro; Ch Pott; J J M van Dongen
Journal:  Leukemia       Date:  2006-12-14       Impact factor: 11.528

4.  Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors.

Authors:  A Ikegame; S Ozaki; D Tsuji; T Harada; S Fujii; S Nakamura; H Miki; A Nakano; K Kagawa; K Takeuchi; M Abe; K Watanabe; M Hiasa; N Kimura; Y Kikuchi; A Sakamoto; K Habu; M Endo; K Itoh; H Yamada-Okabe; T Matsumoto
Journal:  Leukemia       Date:  2012-03-20       Impact factor: 11.528

Review 5.  Pathogenesis of myeloma.

Authors:  Kenneth C Anderson; Ruben D Carrasco
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

6.  Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract.

Authors:  Sabine Ottinger; Anne Klöppel; Vanessa Rausch; Li Liu; Georgios Kallifatidis; Wolfgang Gross; Martha-Maria Gebhard; Franz Brümmer; Ingrid Herr
Journal:  Int J Cancer       Date:  2011-07-21       Impact factor: 7.396

7.  Transforming growth factor β1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma.

Authors:  Haixia Zhang; Haotong Wu; Junheng Zheng; Pei Yu; Lixiao Xu; Pan Jiang; Jin Gao; Hua Wang; Yan Zhang
Journal:  Stem Cells       Date:  2013-03       Impact factor: 6.277

8.  Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.

Authors:  Jianguo Wen; Yongdong Feng; Wanting Huang; Haiyun Chen; Bing Liao; Lawrence Rice; Hector A Preti; Rammurti T Kamble; Youli Zu; Douglas J Ballon; Chung-Che Chang
Journal:  Leuk Res       Date:  2009-07-15       Impact factor: 3.156

9.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.

Authors:  Maria M Ho; Alvin V Ng; Stephen Lam; Jaclyn Y Hung
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

Review 10.  Hypoxia-inducible factors in stem cells and cancer.

Authors:  Jolly Mazumdar; Vijay Dondeti; M Celeste Simon
Journal:  J Cell Mol Med       Date:  2009-11-09       Impact factor: 5.310

View more
  9 in total

1.  Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.

Authors:  Ailing Lu; Manuel A Pallero; Weiqi Lei; Huixian Hong; Yang Yang; Mark J Suto; Joanne E Murphy-Ullrich
Journal:  Am J Pathol       Date:  2016-01-20       Impact factor: 4.307

2.  Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells.

Authors:  Jeanine Schibler; Ann M Tomanek-Chalkley; Jessica L Reedy; Fenghuang Zhan; Douglas R Spitz; Michael K Schultz; Apollina Goel
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

3.  Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.

Authors:  Jianguo Wen; Wenjing Tao; Suyang Hao; Youli Zu
Journal:  J Hematol Oncol       Date:  2017-06-13       Impact factor: 17.388

4.  Acquisition of a side population fraction augments malignant phenotype in ovarian cancer.

Authors:  Koji Yamanoi; Tsukasa Baba; Kaoru Abiko; Junzo Hamanishi; Ken Yamaguchi; Ryusuke Murakami; Mana Taki; Yuko Hosoe; Susan K Murphy; Ikuo Konishi; Masaki Mandai; Noriomi Matsumura
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

5.  ALCAM regulates multiple myeloma chemoresistant side population.

Authors:  Fangfang Wang; Zhang Dan; Hongmei Luo; Jingcao Huang; Yushan Cui; Hong Ding; Juan Xu; Zhimei Lin; Yuhan Gao; Xinyu Zhai; Yan Yang; Ying Qu; Li Zhang; Fengjiao Chen; Qiang Wang; Xin Wang; Yu Feng; Ting Liu; Qing Yi; Ting Niu; Yuhuan Zheng
Journal:  Cell Death Dis       Date:  2022-02-10       Impact factor: 8.469

6.  SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma.

Authors:  Jian Wu; Min Zhang; Omar Faruq; Eldad Zacksenhaus; Wenming Chen; Aijun Liu; Hong Chang
Journal:  Biomark Res       Date:  2021-06-16

7.  Stage-specific embryonic antigen: determining expression in canine glioblastoma, melanoma, and mammary cancer cells.

Authors:  Weiming Lin; Jaime F Modiano; Daisuke Ito
Journal:  J Vet Sci       Date:  2017-03-30       Impact factor: 1.672

8.  CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.

Authors:  Hiroko Nishida; Mutsumi Hayashi; Chikao Morimoto; Michiie Sakamoto; Taketo Yamada
Journal:  Blood Cancer J       Date:  2018-10-22       Impact factor: 11.037

9.  Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.

Authors:  Alejandra Leivas; Ruth M Risueño; Alma Guzmán; Laura Sánchez-Vega; Manuel Pérez; Diego Megías; Lucía Fernández; Rafael Alonso; Antonio Pérez-Martínez; Inmaculada Rapado; Joaquín Martínez-López
Journal:  Cancer Immunol Immunother       Date:  2021-03-10       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.